Literature DB >> 20385467

Aggressive treatment of idiopathic axillo-subclavian vein thrombosis provides excellent long-term function.

David H Stone1, Salvatore T Scali, Aja A Bjerk, Eva Rzucidlo, Catherine K Chang, Philip P Goodney, Brian W Nolan, Daniel B Walsh.   

Abstract

OBJECTIVE: While much attention has been devoted toward treatment paradigms for idiopathic axillo-subclavian vein thrombosis (ASVT), little has focused on long-term durability of aggressive treatment and its associated functional outcomes. The purpose of this study was to review our own surgical therapeutic algorithm and its associated durability and functional outcomes.
METHODS: All patients treated with combined endovascular and open surgery at Dartmouth-Hitchcock Medical Center for ASVT from 1988 to 2008 were identified. Patient demographics, comorbidities, and operative techniques were recorded. Patency, freedom from reintervention, and functional outcomes were documented. Follow-up via telephone and clinic visit allowed quantitative comparison of functional status, pre- and postoperatively.
RESULTS: Thirty-six patients were treated for ASVT throughout the study interval. Seven patients (19.4%) were lost to follow-up. Most patients were male (66%; N = 24); mean age was 32 years. Catheter-directed thrombolysis was utilized in the majority of patients (83.3%; N = 30) with an average time from symptom onset to lysis of 12 days. Surgical decompression was undertaken in all patients via transaxillary (52%; N = 19), supraclavicular (31%; N = 11), or infraclavicular approaches (17%; N = 6). Eleven stents were placed in 11 patients (30.5%) for residual stenotic disease. Mean follow-up was 65 months, with 1- and 5-year overall patency at 100% and 94%, respectively. Freedom from reintervention was 100% and 74.4% at 1 and 5 years, respectively. Seven patients (19.4%) required postoperative reintervention with four receiving additional lytic therapy, two requiring a stent, and one venoplasty. At presentation, 65.5% (N = 19) of patients were unable to work or perform routine activities. After treatment, 86% (N = 25) returned to their employment and have experienced sustained symptomatic and functional improvement.
CONCLUSIONS: Patients with symptomatic idiopathic axillo-subclavian vein thrombosis can expect durable patency with sustained freedom from reintervention following aggressive combined endovascular and surgical treatment. Good functional outcomes can be expected in patients with relief of symptoms and return to work. Copyright (c) 2010 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20385467      PMCID: PMC5240840          DOI: 10.1016/j.jvs.2010.01.091

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  13 in total

1.  Safety and efficacy of early surgical decompression of the thoracic outlet for Paget-Schroetter syndrome.

Authors:  N Angle; H A Gelabert; M M Farooq; S S Ahn; D R Caswell; J A Freischlag; H I Machleder
Journal:  Ann Vasc Surg       Date:  2001-01       Impact factor: 1.466

2.  Conventional versus thrombolytic therapy in spontaneous (effort) axillary-subclavian vein thrombosis.

Authors:  A F AbuRahma; D Sadler; P Stuart; M Z Khan; J P Boland
Journal:  Am J Surg       Date:  1991-04       Impact factor: 2.565

3.  Axillary subclavian vein thrombosis. Changing patterns of etiology, diagnostic, and therapeutic modalities.

Authors:  A F Aburahma; D L Sadler; P A Robinson
Journal:  Am Surg       Date:  1991-02       Impact factor: 0.688

4.  Hemodynamic and morphologic evaluation of sequelae of primary upper extremity deep venous thromboses treated with anticoagulation.

Authors:  Lena M Persson; Thomas Arnhjort; Gerd Lärfars; Stefan Rosfors
Journal:  J Vasc Surg       Date:  2006-06       Impact factor: 4.268

Review 5.  A unified approach to axillosubclavian venous thrombosis in a single hospital admission.

Authors:  David J Caparrelli; Julie Freischlag
Journal:  Semin Vasc Surg       Date:  2005-09       Impact factor: 1.000

6.  Claviculectomy for subclavian venous repair: long-term functional results.

Authors:  R M Green; D Waldman; K Ouriel; P Riggs; J A Deweese
Journal:  J Vasc Surg       Date:  2000-08       Impact factor: 4.268

7.  Long-term results in patients treated with thrombolysis, thoracic inlet decompression, and subclavian vein stenting for Paget-Schroetter syndrome.

Authors:  P B Kreienberg; B B Chang; R C Darling; S P Roddy; P S Paty; W E Lloyd; D Cohen; B Stainken; D M Shah
Journal:  J Vasc Surg       Date:  2001-02       Impact factor: 4.268

8.  Comprehensive surgical management of the competitive athlete with effort thrombosis of the subclavian vein (Paget-Schroetter syndrome).

Authors:  Spencer J Melby; Suresh Vedantham; Vamsidhar R Narra; George A Paletta; Lynnette Khoo-Summers; Matt Driskill; Robert W Thompson
Journal:  J Vasc Surg       Date:  2008-02-14       Impact factor: 4.268

9.  Circumferential venolysis and paraclavicular thoracic outlet decompression for "effort thrombosis" of the subclavian vein.

Authors:  R W Thompson; P A Schneider; N A Nelken; C G Skioldebrand; R J Stoney
Journal:  J Vasc Surg       Date:  1992-11       Impact factor: 4.268

10.  Effort-related axillosubclavian vein thrombosis. A new theory of pathogenesis and a plea for direct surgical intervention.

Authors:  S Aziz; C J Straehley; T J Whelan
Journal:  Am J Surg       Date:  1986-07       Impact factor: 2.565

View more
  3 in total

Review 1.  The infraclavicular approach for Paget-Schroetter syndrome.

Authors:  G Samoila; C P Twine; I M Williams
Journal:  Ann R Coll Surg Engl       Date:  2018-02       Impact factor: 1.891

2.  Venous thoracic outlet syndrome secondary to arterial stent implantation: A case report.

Authors:  Yang Liu; Zhoupeng Wu; Bin Huang; Yi Yang; Jichun Zhao; Yukui Ma
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

3.  Early outcomes using dedicated venous stents in the upper limb of patients with venous thoracic outlet syndrome: A single centre experience.

Authors:  Saissan Rajendran; Tommy Y Cai; Jacky Loa; Prakash Saha; Steven Dubenec
Journal:  CVIR Endovasc       Date:  2019-07-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.